In a recent study published in the journal Nano Today, researchers reviewed non-viral nano-vectors used for delivering the clustered regularly interspaced short palindromic repeats ...
Dyno Therapeutics launches Dyno-yp2, a top-performing TfR1-mediated AAV capsid, to further diversify CNS delivery portfolio ...
Vector BioPharma AG (Vector BioPharma), a biopharmaceutical company aiming to transform the safety, efficacy, and specificity of drug delivery to improve treatments for patients, today announced that ...
Vector BioPharma is taking a different approach with a delivery vehicle that’s like a virus, but devoid of the features that limit viral vectors. The Basel, Switzerland-based company formally launched ...
Versant Ventures has committed $30 million to improve gene delivery. By pumping the cash into Vector BioPharma, the VC is aiming to address the limitations of existing systems such as the cap on the ...
The vector consists of a polyethylene glycolylated liposomal outer coat (providing immune evasion and prolonged circulation), a spindle-shaped nanomotor (resembling a flagellum, facilitating targeted ...
Some of the newest and most exciting gene therapy technologies share a problem: They’re too bulky. They rely on multiple functional DNA and protein elements that must reach target cells all at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback